The recently-launched Research on Research Institute aims to deliver “transformative and translational research on research systems, cultures, and decision-making,” the need for which “has never been more vital,” says director.
Iqvia’s Orchestrated Patient Engagement solution, powered by Belong.Life, delivers ‘hyper-personalized’ content to engage and support patients, providing insights that will benefit patients, life sciences companies, and the health care system, says CEO.
Phastar is building up its data science group as AI and machine learning ‘are rapidly modernizing clinical trials’ and Synteract boosts its centers of development in oncology and rare/orphan diseases, among other people on the move this month.
There has been a lot of discussion surrounding the use of artificial intelligence in drug development – with several deals, alliances, and partnerships made so far this year. Here, Outsourcing-Pharma takes a look back at some of these announcements, as...
South Korea looks to accelerate review timelines and study start-up with a new five-year plan that will benefit biotechs looking for locations outside the US to ‘ramp up’ clinical development programs, says CRO.
The FDA has extended its agreement with CluePoints to augment the agency’s oversight of clinical trials using data-driven approaches, with additional testing ideas focusing on moderators of treatment effect and real-world evidence, says CCO.
Fewer investigators cite patient recruitment as a top challenge in a recent report which finds investigators also more willing to participate in future clinical trials if working with a preferred central lab.
Increasingly complex clinical trials are putting pressure on CROs to expand their service offerings in what has been a historically monolithic space – with diagnostics also continuing to play a more important role in the market, says industry expert.
The last month of summer saw several hires, including a lead for Worldwide Clinical Trials’ Japan operations, CEO appointments at CordenPharma and LabConnect, and Altasciences’ new CSO, who joins the company from Syneos.
The FDA this week released a new draft guidance encouraging the inclusion of male patients in breast cancer clinical trials, the incidence of which has increased approximately 26% over the last 25 years.